skip to main content

ASDAS Biologic Eligibility — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateSpondyloarthropathyASDAS Biologic EligibilitySCE Rheumatology

A 42-year-old man with radiographic axial spondyloarthritis has persistent inflammatory spinal symptoms despite adequate trials of two NSAIDs. His BASDAI is 7.5, spinal pain visual analogue scale is 7 cm and ASDAS-CRP is 4.2. Which statement most accurately describes the role of ASDAS when considering biologic or targeted synthetic DMARD treatment in current UK practice?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — ASDAS of at least 2.1 denotes high disease activity, but UK eligibility still uses BASDAI, spinal pain and NSAID criteria.

Explanation lettering: E = shown as A · C = shown as B · D = shown as C · B = shown as D · A = shown as E

An ASDAS of at least 2.1 denotes high disease activity and is used in the ASAS-EULAR treatment-escalation framework; this patient's ASDAS of 4.2 represents very high disease activity. However, ASDAS alone does not determine NHS eligibility. Current NICE criteria for radiographic axSpA require BASDAI at least 4, spinal pain VAS at least 4 cm and inadequate control with, or unsuitability of, NSAIDs. BSR 2025 promotes ASDAS-informed assessment and uses an ASDAS reduction of at least 1.1 to assess response. Option A confuses the very-high-disease-activity boundary with an eligibility threshold. Option B omits spinal pain and NSAID requirements. Options C and E use unsupported thresholds. The original item incorrectly converted the ASDAS 2.1 disease-activity boundary into a repeated UK eligibility criterion.

Reference: NICE. TA383, TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis, recommendations, published 2016 and editorially updated December 2025: https://www.nice.org.uk/guidance/TA383/chapter/1-recommendations